ASCO 2024 | The future of OBX-115, a novel TIL, in the melanoma treatment landscape
Rodabe Navroze Amaria, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on how OBX-115, an IL2-sparing autologous engineered tumor-infiltrating lymphocyte (TIL), can provide a potential treatment alternative for patients with melanoma. Whilst findings from the Phase I study (NCT05470283) show encouraging outcomes, more research is needed. An ongoing Phase I/II multicenter study (NCT06060613) is underway. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Bristol-Myers Squibb/Medarex; Erasca, Inc; Iovance Biotherapeutics; Novartis; Obsidian Therapeutics
Research Funding – Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst)
